Goldman Sachs FICC Revenue Falls 10% Amid Iran War Market Volatility 
DEEPX Partners with Hyundai to Power Next-Gen AI Robots Ahead of IPO 
TSMC Posts Record Q1 Profit Fueled by AI Chip Demand 
Samsung Races to Deliver Next-Gen HBM4E Memory Samples to Nvidia 
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
KKR's $820M Investment Fuels Samsung SDS AI Expansion, Sending Group Shares Soaring 
Sam Altman Moves to Dismiss Punitive Damages in Sister's Sexual Abuse Lawsuit 
Uber Bets Big on Autonomous Vehicles with $10 Billion Commitment 
How Technology Is Reshaping Modern Business: From Operations to Customer Experience 
Federal Judge Dismisses DOJ Lawsuit Attempting to Block Hawaii's Climate Case Against Oil Giants 
Elliott Investment Takes ~3% Stake in Daikin, Pushes for Buybacks and Strategic Overhaul 
Apple Wins ITC Ruling, Keeping Blood-Oxygen Feature on Apple Watch 
Tesla's Terafab: AI Chip Factory Eyes Taiwan's Semiconductor Talent 
Hermès Q1 2026 Sales Miss Expectations Amid Iran War and China Slowdown 
Daikin Industries Stock Surges 14% After Elliott Investment Management Discloses Major Stake 
Federal Agencies Secretly Test Anthropic's AI Despite Trump Administration Ban 
Elon Musk's Terafab Foundry Courts Top Chipmaking Giants for AI Self-Sufficiency Push 
 - EconoTimes)
RALEIGH, N.C., March 31, 2016 -- PRA Health Sciences (PRA) (NASDAQ:PRAH), is pleased to announce that it received a “Highly Commended” designation by Vaccine Industry Excellence (ViE) for Best Contract Research Organization. PRA was originally named a finalist in the category based on industry nominations. Finalists submitted a detailed questionnaire about their vaccine capabilities which was then blinded, reviewed, and rated by a panel of judges.
“This is a great honor,” said Frank Hijek, PRA Senior Vice President, Strategic Drug Development. “By combining PRA’s therapeutic expertise and experience with proven strategies and innovative approaches, we are redefining vaccine clinical research. This recognition speaks to our commitment to accelerate vaccine development.”
PRA’s vaccine experience includes Phase I - Phase IV adult and pediatric studies involving nearly 213,000 study participants at more than 3,000 sites around the world. In the past five years, PRA teams have participated in over 140 vaccine studies; these include studies that led to the approval of six vaccines that are currently on the market. More information about PRA’s Vaccine Solutions group can be found at www.pravaccinesolutions.com.
ABOUT PRA HEALTH SCIENCES
PRA is one of the world's leading global contract research organizations, by revenue, providing outsourced clinical development services to the biotechnology and pharmaceutical industries. PRA’s global clinical development platform includes approximately 70 offices across North America, Europe, Asia, Latin America, South Africa, Australia and the Middle East, and approximately 12,000 employees worldwide. Since 2000, PRA has performed approximately 3,300 clinical trials worldwide and has worked on more than 100 marketed drugs across several therapeutic areas. In addition, PRA has participated in the pivotal or supportive trials that led to U.S. Food and Drug Administration or international regulatory approval of more than 60 drugs. To learn more about PRA, please visit www.prahs.com.
INQUIRIES: Christine Rogers, Manager - Public Relations, Corporate Communications EMAIL: [email protected] PHONE: +1 919.786.8463
